{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:31:37Z","timestamp":1792524697103,"version":"4.5.0"},"reference-count":201,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Breast cancer survivors experience unique treatment-related side effects that have long-standing and life-altering implications. These remain a challenging aspect both in terms of diagnosis and management for these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This article is a review of the latest key literature in the management of common side effects of treatment in breast cancer survivors namely infertility, vasomotor symptoms, sexual dysfunction, peripheral neuropathy, lymphedema, musculoskeletal symptoms, anthracycline-related cardiotoxicity, secondary malignancies, role of ctDNA, lifestyle modifications, strategies to maintain bone mineral density and addressing fear of cancer recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Recent research in the field has led to novel advancements for survivors planning a family, pharmacotherapeutic options for hot flashes, overcoming barriers such as adherence to therapy and management of long-term side effects, and a incorporating a multimodal approach to improve sexual health in women, neuropathy, musculoskeletal issues and lymphedema.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>There have been significant strides in the understanding and management of issues in breast cancer survivors. The increasing awareness and multimodal approach will continue to improve outcomes for survivors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11912-025-01687-x","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T01:50:33Z","timestamp":1749779433000},"page":"986-1001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Addressing the Needs of Breast Cancer Survivors"],"prefix":"10.1007","volume":"27","author":[{"given":"Humaira","family":"Sarfraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Tuz","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utsav","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"10074","key":"1687_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134\u201350.","journal-title":"Lancet"},{"issue":"2","key":"1687_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10549-020-06003-8","volume":"186","author":"V Sopik","year":"2021","unstructured":"Sopik V. International variation in breast cancer incidence and mortality in young women. Breast Cancer Res Treat. 2021;186(2):497\u2013507.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1687_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15585\/mmwr.mm7102a2","volume":"71","author":"TD Ellington","year":"2022","unstructured":"Ellington TD, Miller JW, Henley SJ, Wilson RJ, Wu M, Richardson LC. Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged \u226520 Years - United States, 1999\u20132018. MMWR Morb Mortal Wkly Rep. 2022;71(2):43\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1687_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/annonc\/mdx757","volume":"29","author":"K Jordan","year":"2018","unstructured":"Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scott\u00e9 F, Strasser F, et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol. 2018;29(1):36\u201343.","journal-title":"Ann Oncol"},{"issue":"1","key":"1687_CR5","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1687_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40487-023-00225-8","volume":"11","author":"D Soldato","year":"2023","unstructured":"Soldato D, Arecco L, Agostinetto E, Franzoi MA, Mariamidze E, Begijanashvili S, et al. The Future of Breast Cancer Research in the Survivorship Field. Oncol Ther. 2023;11(2):199\u2013229.","journal-title":"Oncol Ther"},{"key":"1687_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.breast.2019.07.001","volume":"47","author":"M Ruggeri","year":"2019","unstructured":"Ruggeri M, Pagan E, Bagnardi V, Bianco N, Gallerani E, Buser K, et al. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers. Breast. 2019;47:85\u201392.","journal-title":"Breast"},{"issue":"11","key":"1687_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1200\/JCO.2013.52.8877","volume":"32","author":"KJ Ruddy","year":"2014","unstructured":"Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151\u20136.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1687_CR9","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1002\/cncr.33596","volume":"127","author":"T Sella","year":"2021","unstructured":"Sella T, Poorvu PD, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, et al. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer. 2021;127(16):2888\u201394.","journal-title":"Cancer"},{"key":"1687_CR10","first-page":"341","volume":"13","author":"V Martelli","year":"2021","unstructured":"Martelli V, Latocca MM, Ruelle T, Perachino M, Arecco L, Beshiri K, et al. Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. Breast Cancer (Dove Med Press). 2021;13:341\u201351.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"12","key":"1687_CR11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","volume":"31","author":"M Lambertini","year":"2020","unstructured":"Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines(\u2020). Ann Oncol. 2020;31(12):1664\u201378.","journal-title":"Ann Oncol"},{"key":"1687_CR12","doi-asserted-by":"crossref","unstructured":"Anderson RA, Amant F, Braat D, D'Angelo A, Chuva de Sousa Lopes SM, Demeestere I, et al ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4):hoaa052.","DOI":"10.1093\/hropen\/hoaa052"},{"issue":"6","key":"1687_CR13","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/cncr.26459","volume":"118","author":"JM Letourneau","year":"2012","unstructured":"Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710\u20137.","journal-title":"Cancer"},{"key":"1687_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ctrv.2018.11.006","volume":"72","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. Cancer Treat Rev. 2019;72:65\u201377.","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"1687_CR15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","volume":"36","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, et al. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2018;36(19):1981\u201390.","journal-title":"J Clin Oncol"},{"issue":"29","key":"1687_CR16","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.21.00535","volume":"39","author":"M Lambertini","year":"2021","unstructured":"Lambertini M, Blondeaux E, Bruzzone M, Perachino M, Anderson RA, de Azambuja E, et al. Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol. 2021;39(29):3293\u2013305.","journal-title":"J Clin Oncol"},{"key":"1687_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.breast.2018.08.099","volume":"42","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, Del Mastro L, et al. The BCY3\/BCC 2017 survey on physicians\u2019 knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast. 2018;42:41\u20139.","journal-title":"Breast"},{"key":"1687_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2022.06.048","volume":"173","author":"RA Anderson","year":"2022","unstructured":"Anderson RA, Lambertini M, Hall PS, Wallace WH, Morrison DS, Kelsey TW. Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. Eur J Cancer. 2022;173:113\u201322.","journal-title":"Eur J Cancer"},{"issue":"14","key":"1687_CR19","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","volume":"34","author":"HJ Burstein","year":"2016","unstructured":"Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016;34(14):1689\u2013701.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1687_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/jnci\/djx206","volume":"110","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, et al. Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. J Natl Cancer Inst. 2018;110(4):426\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"1687_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.breast.2021.07.021","volume":"59","author":"AH Partridge","year":"2021","unstructured":"Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, et al. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021;59:327\u201338.","journal-title":"Breast"},{"issue":"18","key":"1687_CR22","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","volume":"388","author":"AH Partridge","year":"2023","unstructured":"Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med. 2023;388(18):1645\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"1687_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/PPO.0b013e3181976602","volume":"15","author":"C Duffy","year":"2009","unstructured":"Duffy C, Allen S. Medical and psychosocial aspects of fertility after cancer. Cancer J. 2009;15(1):27\u201333.","journal-title":"Cancer J"},{"issue":"1","key":"1687_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(1):33\u201347.","journal-title":"Ann Oncol"},{"key":"1687_CR25","doi-asserted-by":"crossref","unstructured":"Blondeaux E, et al. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol. 2025;26(6):759\u201370.","DOI":"10.1016\/S1470-2045(25)00152-4"},{"issue":"18","key":"1687_CR26","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1200\/JCO.20.02880","volume":"39","author":"V Turan","year":"2021","unstructured":"Turan V, Lambertini M, Lee DY, Wang E, Clatot F, Karlan BY, et al. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data. J Clin Oncol. 2021;39(18):2016\u201324.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1687_CR27","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2012.47.7893","volume":"31","author":"A Valentini","year":"2013","unstructured":"Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, et al. Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2013;31(31):3914\u20139.","journal-title":"J Clin Oncol"},{"issue":"5s","key":"1687_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","volume":"16","author":"JA Thompson","year":"2018","unstructured":"Thompson JA. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. J Natl Compr Canc Netw. 2018;16(5s):594\u20136.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"1687_CR29","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","volume":"22","author":"MA Franzoi","year":"2021","unstructured":"Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303\u201313.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1687_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","volume":"13","author":"E Mann","year":"2012","unstructured":"Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309\u201318.","journal-title":"Lancet Oncol"},{"issue":"9488","key":"1687_CR31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","volume":"366","author":"KJ Pandya","year":"2005","unstructured":"Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9488):818\u201324.","journal-title":"Lancet"},{"issue":"1","key":"1687_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"9247","key":"1687_CR33","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","volume":"356","author":"CL Loprinzi","year":"2000","unstructured":"Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059\u201363.","journal-title":"Lancet"},{"issue":"6","key":"1687_CR34","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO.2002.20.6.1578","volume":"20","author":"CL Loprinzi","year":"2002","unstructured":"Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol. 2002;20(6):1578\u201383.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1687_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.1994.12.1.155","volume":"12","author":"RM Goldberg","year":"1994","unstructured":"Goldberg RM, Loprinzi CL, O\u2019Fallon JR, Veeder MH, Miser AW, Mailliard JA, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994;12(1):155\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1687_CR36","doi-asserted-by":"publisher","first-page":"pkz088","DOI":"10.1093\/jncics\/pkz088","volume":"4","author":"RA Leon-Ferre","year":"2020","unstructured":"Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, et al. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectr. 2020;4(1):pkz088.","journal-title":"JNCI Cancer Spectr."},{"issue":"10382","key":"1687_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091\u2013102.","journal-title":"Lancet"},{"issue":"2","key":"1687_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4103\/0973-1482.172716","volume":"12","author":"YP Chen","year":"2016","unstructured":"Chen YP, Liu T, Peng YY, Wang YP, Chen H, Fan YF, et al. Acupuncture for hot flashes in women with breast cancer: A systematic review. J Cancer Res Ther. 2016;12(2):535\u201342.","journal-title":"J Cancer Res Ther"},{"issue":"6","key":"1687_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100300","volume":"6","author":"M Condorelli","year":"2021","unstructured":"Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy AS, et al. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1\/2 with a pregnancy after prior history of breast cancer. ESMO Open. 2021;6(6): 100300.","journal-title":"ESMO Open"},{"issue":"1","key":"1687_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jsxm.2020.10.016","volume":"18","author":"CCM Dos Santos","year":"2021","unstructured":"Dos Santos CCM, Uggioni MLR, Colonetti T, Colonetti L, Grande AJ, Da Rosa MI. Hyaluronic Acid in Postmenopause Vaginal Atrophy: A Systematic Review. J Sex Med. 2021;18(1):156\u201366.","journal-title":"J Sex Med"},{"issue":"30","key":"1687_CR41","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","volume":"33","author":"MF Goetsch","year":"2015","unstructured":"Goetsch MF, Lim JY, Caughey AB. A Practical Solution for Dyspareunia in Breast Cancer Survivors: A Randomized Controlled Trial. J Clin Oncol. 2015;33(30):3394\u2013400.","journal-title":"J Clin Oncol"},{"key":"1687_CR42","doi-asserted-by":"crossref","unstructured":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888\u2013902; quiz 3\u20134.","DOI":"10.1097\/GME.0b013e3182a122c2"},{"issue":"4","key":"1687_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jpag.2019.05.002","volume":"32","author":"AM Amies Oelschlager","year":"2019","unstructured":"Amies Oelschlager AM, Debiec K. Vaginal Dilator Therapy: A Guide for Providers for Assessing Readiness and Supporting Patients Through the Process Successfully. J Pediatr Adolesc Gynecol. 2019;32(4):354\u20138.","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"3","key":"1687_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/GME.0000000000001463","volume":"27","author":"RJ Santen","year":"2020","unstructured":"Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361\u201370.","journal-title":"Menopause"},{"issue":"2","key":"1687_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","volume":"135","author":"I Le Ray","year":"2012","unstructured":"Le Ray I, Dell\u2019Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"1687_CR46","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djac112","volume":"114","author":"S Cold","year":"2022","unstructured":"Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. J Natl Cancer Inst. 2022;114(10):1347\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1687_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","volume":"10","author":"L McVicker","year":"2024","unstructured":"McVicker L, Labeit AM, Coupland CAC, Hicks B, Hughes C, McMenamin \u00da, et al. Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol. 2024;10(1):103\u20138.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1687_CR48","first-page":"643","volume":"26","author":"DL Barton","year":"2018","unstructured":"Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(2):643\u201350.","journal-title":"Support Care Cancer"},{"issue":"6","key":"1687_CR49","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/GME.0000000000001121","volume":"25","author":"SS Faubion","year":"2018","unstructured":"Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women\u2019s Sexual Health. Menopause. 2018;25(6):596\u2013608.","journal-title":"Menopause"},{"issue":"5","key":"1687_CR50","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s10103-018-2471-3","volume":"33","author":"A Becorpi","year":"2018","unstructured":"Becorpi A, Campisciano G, Zanotta N, Tredici Z, Guaschino S, Petraglia F, et al. Fractional CO(2) laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. Lasers Med Sci. 2018;33(5):1047\u201354.","journal-title":"Lasers Med Sci"},{"issue":"14","key":"1687_CR51","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2021.14892","volume":"326","author":"FG Li","year":"2021","unstructured":"Li FG, Maheux-Lacroix S, Deans R, Nesbitt-Hawes E, Budden A, Nguyen K, et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. JAMA. 2021;326(14):1381\u20139.","journal-title":"JAMA"},{"key":"1687_CR52","unstructured":"Nicoli Serquiz NS, Ayane C A Sarmento, Natalie R Almeida, Maria Lu\u00edsa Nobre, Kleyton S Medeiros, Antonio C Q Aquino, Juliana D A S Camargo, Heitor D Medeiros, Beatriz B Siqueira, Ronnier Oliveira, N\u00edcolas C Conrado, Larissa P Moura, Raphael M Carvalho, Ana Katherine Gon\u00e7alves. Use of intravaginal physical energy for treating genitourinary syndrome of menopause in breast cancer survivors: a systematic review. SABCS Abstract Number: SESS-3559. 2024.\u00a0https:\/\/sabcs.org\/Portals\/0\/Documents\/FINAL%20SABCS%2024%20%20Poster%20Session%201%20.pdf?ver=COtfEZSxfP5lWkHrNkFAqg%3D%3D."},{"key":"1687_CR53","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390442","volume":"43","author":"M Lambertini","year":"2023","unstructured":"Lambertini M, Arecco L, Woodard TL, Messelt A, Rojas KE. Advances in the Management of Menopausal Symptoms, Fertility Preservation, and Bone Health for Women With Breast Cancer on Endocrine Therapy. Am Soc Clin Oncol Educ Book. 2023;43: e390442.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1687_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1196\/annals.1413.014","volume":"1131","author":"SG Rockson","year":"2008","unstructured":"Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147\u201354.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"1687_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10549-004-2045-x","volume":"89","author":"S Hayes","year":"2005","unstructured":"Hayes S, Cornish B, Newman B. Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat. 2005;89(3):221\u20136.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1687_CR56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/lrb.2016.0045","volume":"16","author":"ZE Iyigun","year":"2018","unstructured":"Iyigun ZE, Duymaz T, Ilgun AS, Alco G, Ordu C, Sarsenov D, et al. Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer. Lymphat Res Biol. 2018;16(1):28\u201335.","journal-title":"Lymphat Res Biol"},{"issue":"6","key":"1687_CR57","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jpainsymman.2009.04.030","volume":"38","author":"MR Fu","year":"2009","unstructured":"Fu MR, Rosedale M. Breast cancer survivors\u2019 experiences of lymphedema-related symptoms. J Pain Symptom Manage. 2009;38(6):849\u201359.","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"1687_CR58","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1200\/JCO.2015.61.5948","volume":"34","author":"CM Ferguson","year":"2016","unstructured":"Ferguson CM, Swaroop MN, Horick N, Skolny MN, Miller CL, Jammallo LS, et al. Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer. J Clin Oncol. 2016;34(7):691\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1687_CR59","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/lrb.2017.0067","volume":"16","author":"AJM Cornelissen","year":"2018","unstructured":"Cornelissen AJM, Beugels J, Ewalds L, Heuts EM, Keuter XHA, Piatkowski A, et al. Effect of Lymphaticovenous Anastomosis in Breast Cancer-Related Lymphedema: A Review of the Literature. Lymphat Res Biol. 2018;16(5):426\u201334.","journal-title":"Lymphat Res Biol"},{"issue":"6","key":"1687_CR60","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/micr.22254","volume":"34","author":"F Boccardo","year":"2014","unstructured":"Boccardo F, Casabona F, De Cian F, Friedman D, Murelli F, Puglisi M, et al. Lymphatic microsurgical preventing healing approach (LYMPHA) for primary surgical prevention of breast cancer-related lymphedema: over 4 years follow-up. Microsurgery. 2014;34(6):421\u20134.","journal-title":"Microsurgery"},{"issue":"4","key":"1687_CR61","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/SLA.0000000000005952","volume":"278","author":"M Coriddi","year":"2023","unstructured":"Coriddi M, Dayan J, Bloomfield E, McGrath L, Diwan R, Monge J, et al. Efficacy of Immediate Lymphatic Reconstruction to Decrease Incidence of Breast Cancer-related Lymphedema: Preliminary Results of Randomized Controlled Trial. Ann Surg. 2023;278(4):630\u20137.","journal-title":"Ann Surg"},{"issue":"1","key":"1687_CR62","first-page":"56","volume":"32","author":"H Brorson","year":"2016","unstructured":"Brorson H. Liposuction in Lymphedema Treatment. J Reconstr Microsurg. 2016;32(1):56\u201365.","journal-title":"J Reconstr Microsurg"},{"issue":"10","key":"1687_CR63","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1245\/s10434-017-5982-4","volume":"24","author":"SA McLaughlin","year":"2017","unstructured":"McLaughlin SA, Staley AC, Vicini F, Thiruchelvam P, Hutchison NA, Mendez J, et al. Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel\u202f: Part 1: Definitions, Assessments, Education, and Future Directions. Ann Surg Oncol. 2017;24(10):2818\u201326.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1687_CR64","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1200\/JCO.21.01681","volume":"40","author":"BS Rafn","year":"2022","unstructured":"Rafn BS, Christensen J, Larsen A, Bloomquist K. Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis. J Clin Oncol. 2022;40(9):1009\u201326.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1687_CR65","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMcp1803290","volume":"379","author":"SG Rockson","year":"2018","unstructured":"Rockson SG. Lymphedema after Breast Cancer Treatment. N Engl J Med. 2018;379(20):1937\u201344.","journal-title":"N Engl J Med"},{"key":"1687_CR66","unstructured":"version 5.2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419. Accessed 22 Apr 2025.\u00a0"},{"key":"1687_CR67","doi-asserted-by":"crossref","unstructured":"Barroso-Sousa R BW, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. JAMA Oncol. 2018;1;4(2):173.","DOI":"10.1001\/jamaoncol.2017.3064"},{"issue":"3","key":"1687_CR68","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1007\/s12020-024-03859-4","volume":"85","author":"R Gao","year":"2024","unstructured":"Gao R, Li C, Zhang S, Liao N, Guan H. Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study. Endocrine. 2024;85(3):1446\u201355.","journal-title":"Endocrine"},{"issue":"5","key":"1687_CR69","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255\u201368.","journal-title":"J Am Acad Dermatol"},{"key":"1687_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588582","volume":"11","author":"CD Sadik","year":"2020","unstructured":"Sadik CD, Langan EA, Gutzmer R, Fleischer MI, Loquai C, Reinhardt L, et al. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers. Front Immunol. 2020;11: 588582.","journal-title":"Front Immunol"},{"issue":"5","key":"1687_CR71","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamadermatol.2024.0390","volume":"160","author":"P Aggarwal","year":"2024","unstructured":"Aggarwal P, Clark D, Shah A, Rismiller K, Neltner SA. Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use. JAMA Dermatol. 2024;160(5):573\u20135.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1687_CR72","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017;35(7):709\u201317.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1687_CR73","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2217\/fon-2019-0102","volume":"15","author":"T Baba","year":"2019","unstructured":"Baba T, Sakai F, Kato T, Kusumoto M, Kenmotsu H, Sugiura H, et al. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. Future Oncol. 2019;15(16):1911\u201320.","journal-title":"Future Oncol"},{"issue":"1","key":"1687_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06480-5","volume":"192","author":"O Gumusay","year":"2022","unstructured":"Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. Breast Cancer Res Treat. 2022;192(1):1\u201317.","journal-title":"Breast Cancer Res Treat"},{"issue":"48","key":"1687_CR75","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","volume":"42","author":"C Dolladille","year":"2021","unstructured":"Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E, Sassier M, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021;42(48):4964\u201377.","journal-title":"Eur Heart J"},{"issue":"3","key":"1687_CR76","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jpain.2013.11.004","volume":"15","author":"F Laroche","year":"2014","unstructured":"Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, et al. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain. 2014;15(3):293\u2013303.","journal-title":"J Pain"},{"issue":"4","key":"1687_CR77","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","volume":"26","author":"AH Partridge","year":"2008","unstructured":"Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556\u201362.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1687_CR78","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529\u201337.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1687_CR79","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1200\/JCO.2017.74.6651","volume":"36","author":"NL Henry","year":"2018","unstructured":"Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, et al. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol. 2018;36(4):326\u201332.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1687_CR80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-009-0692-7","volume":"120","author":"K Briot","year":"2010","unstructured":"Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127\u201334.","journal-title":"Breast Cancer Res Treat"},{"key":"1687_CR81","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.critrevonc.2017.01.010","volume":"111","author":"K Roberts","year":"2017","unstructured":"Roberts K, Rickett K, Greer R, Woodward N. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;111:66\u201380.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1687_CR82","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s11764-015-0511-6","volume":"10","author":"H Arem","year":"2016","unstructured":"Arem H, Sorkin M, Cartmel B, Fiellin M, Capozza S, Harrigan M, et al. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study. J Cancer Surviv. 2016;10(4):654\u201362.","journal-title":"J Cancer Surviv"},{"issue":"2","key":"1687_CR83","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jama.2018.8907","volume":"320","author":"DL Hershman","year":"2018","unstructured":"Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, et al. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA. 2018;320(2):167\u201376.","journal-title":"JAMA"},{"key":"1687_CR84","doi-asserted-by":"crossref","unstructured":"Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. JNCI: J Nat Cancer Inst. 2018;110(2):djx140.","DOI":"10.1093\/jnci\/djx140"},{"issue":"19","key":"1687_CR85","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1002\/cam4.4202","volume":"10","author":"M Kamgar","year":"2021","unstructured":"Kamgar M, Greenwald MK, Assad H, Hastert TA, McLaughlin EM, Reding KW, et al. Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Med. 2021;10(19):6666\u201376.","journal-title":"Cancer Med"},{"issue":"1","key":"1687_CR86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","volume":"82","author":"AA Argyriou","year":"2012","unstructured":"Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol. 2012;82(1):51\u201377.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"1687_CR87","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11912-023-01449-7","volume":"25","author":"D Molinares","year":"2023","unstructured":"Molinares D, Kurtevski S, Zhu Y. Chemotherapy-Induced Peripheral Neuropathy: Diagnosis, Agents, General Clinical Presentation, and Treatments. Curr Oncol Rep. 2023;25(11):1227\u201335.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1687_CR88","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/neuonc\/nox115","volume":"20","author":"AM Zukas","year":"2018","unstructured":"Zukas AM, Schiff D. Neurological complications of new chemotherapy agents. Neuro Oncol. 2018;20(1):24\u201336.","journal-title":"Neuro Oncol"},{"key":"1687_CR89","doi-asserted-by":"publisher","unstructured":"Markides DM, Hita AG, Merlin J, Reyes-Gibby C, Yeung SJ. Antibody-drug conjugates: the toxicities and adverse effects that emergency physicians must know. Ann Emerg Med. 2025;85(3):214\u201329. https:\/\/doi.org\/10.1016\/j.annemergmed.2024.10.015.","DOI":"10.1016\/j.annemergmed.2024.10.015"},{"issue":"4","key":"1687_CR90","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/bja\/aex229","volume":"119","author":"SJL Flatters","year":"2017","unstructured":"Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br J Anaesth. 2017;119(4):737\u201349.","journal-title":"Br J Anaesth"},{"issue":"2","key":"1687_CR91","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11940-010-0108-3","volume":"13","author":"G Cavaletti","year":"2011","unstructured":"Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E. Chemotherapy-Induced Neuropathy. Curr Treat Options Neurol. 2011;13(2):180\u201390.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"1687_CR92","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/2193-1801-3-366","volume":"3","author":"B Bhatnagar","year":"2014","unstructured":"Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014;3(1):366.","journal-title":"Springerplus"},{"issue":"3","key":"1687_CR93","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10549-022-06670-9","volume":"195","author":"K Engvall","year":"2022","unstructured":"Engvall K, Gr\u00e9en H, Fredrikson M, Lagerlund M, Lewin F, \u00c5vall-Lundqvist E. Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study. Breast Cancer Res Treat. 2022;195(3):379\u201391.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1687_CR94","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10549-017-4437-8","volume":"166","author":"M Mustafa Ali","year":"2017","unstructured":"Mustafa Ali M, Moeller M, Rybicki L, Moore HCF. Long-term peripheral neuropathy symptoms in breast cancer survivors. Breast Cancer Res Treat. 2017;166(2):519\u201326.","journal-title":"Breast Cancer Res Treat"},{"key":"1687_CR95","doi-asserted-by":"crossref","unstructured":"Greenlee H, Hershman DL, Shi Z, Kwan ML, Ergas IJ, Roh JM, et al. BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study. JNCI: J Nat Cancer Inst. 2017;109(2):djw206.","DOI":"10.1093\/jnci\/djw206"},{"issue":"7","key":"1687_CR96","first-page":"2241","volume":"25","author":"SJ Song","year":"2017","unstructured":"Song SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im S-A, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241\u20138.","journal-title":"Support Care Cancer"},{"issue":"25","key":"1687_CR97","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1200\/JCO.2011.39.8446","volume":"30","author":"BP Schneider","year":"2012","unstructured":"Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, et al. Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer. J Clin Oncol. 2012;30(25):3051\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1687_CR98","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","volume":"19","author":"A Molassiotis","year":"2019","unstructured":"Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):132.","journal-title":"BMC Cancer"},{"key":"1687_CR99","doi-asserted-by":"publisher","unstructured":"Schneider BP, Lai D, Shen F, Jiang G, Radovich M, Li L, Gardner L, Miller KD, O'Neill A, Sparano JA, Xue G, Foroud T, Sledge GW Jr. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget. 2016;7(50):82244\u201353. https:\/\/doi.org\/10.18632\/oncotarget.12545.","DOI":"10.18632\/oncotarget.12545"},{"issue":"22","key":"1687_CR100","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-15-0586","volume":"21","author":"BP Schneider","year":"2015","unstructured":"Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, et al. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res. 2015;21(22):5082\u201391.","journal-title":"Clin Cancer Res"},{"key":"1687_CR101","doi-asserted-by":"publisher","unstructured":"Zaj\u0105czkowska R, Kocot-K\u0119pska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https:\/\/doi.org\/10.3390\/ijms20061451.","DOI":"10.3390\/ijms20061451"},{"issue":"17","key":"1687_CR102","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/cncr.32175","volume":"125","author":"KA Nyrop","year":"2019","unstructured":"Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, et al. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. Cancer. 2019;125(17):2945\u201354.","journal-title":"Cancer"},{"issue":"11","key":"1687_CR103","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472\u20138.","journal-title":"J Clin Oncol"},{"key":"1687_CR104","doi-asserted-by":"publisher","first-page":"174480692093650","DOI":"10.1177\/1744806920936502","volume":"16","author":"KM Kober","year":"2020","unstructured":"Kober KM, Lee M-C, Olshen A, Conley YP, Sirota M, Keiser M, et al. Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain. Mol Pain. 2020;16:1744806920936502.","journal-title":"Mol Pain"},{"key":"1687_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110062","volume":"258","author":"C Mortensen","year":"2024","unstructured":"Mortensen C, Thomsen MT, Chua KC, Hammer HS, Nielsen F, P\u00f6tz O, et al. Modeling mechanisms of chemotherapy-induced peripheral neuropathy and chemotherapy transport using induced pluripotent stem cell-derived sensory neurons. Neuropharmacology. 2024;258: 110062.","journal-title":"Neuropharmacology"},{"key":"1687_CR106","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","volume":"2","author":"A Areti","year":"2014","unstructured":"Areti A, Yerra VG, Naidu VGM, Kumar A. Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy. Redox Biol. 2014;2:289\u201395.","journal-title":"Redox Biol"},{"key":"1687_CR107","doi-asserted-by":"publisher","unstructured":"Doyle TM, Janes K, Xiao WH, Kolar GR, Luecke HF, Gratton MA, Tosh DK, Jacobson KA, Bennett GJ, Salvemini D. Mitochondrial A3 adenosine receptor as a mechanism for the protective effects of A3AR agonists on chemotherapy-induced neuropathic pain. J Neurosci. 2025;45(3):e1268242024. https:\/\/doi.org\/10.1523\/JNEUROSCI.1268-24.2024.","DOI":"10.1523\/JNEUROSCI.1268-24.2024"},{"key":"1687_CR108","doi-asserted-by":"publisher","unstructured":"Hassanzadeh E, Sedighi Pashaki A, Akbari Hamed E, Mehrpooya M, Mohammadian K, Bayani R, Sheikhi K, Ranjbar H, Abbasi M. Evaluating N-acetylcysteine as a protective agent against chemotherapy-induced neuropathy in breast cancer: a triple-blind, randomized clinical trial. Am J Clin Oncol. 2025;48(3):122\u20136. https:\/\/doi.org\/10.1097\/COC.0000000000001153.","DOI":"10.1097\/COC.0000000000001153"},{"key":"1687_CR109","doi-asserted-by":"publisher","unstructured":"Chen J, Li H. Characterization of novel SARM1 inhibitors for the treatment of chemotherapy-induced peripheral neuropathy. Biomedicines. 2024;12:2123. https:\/\/doi.org\/10.3390\/biomedicines12092123.","DOI":"10.3390\/biomedicines12092123"},{"key":"1687_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.117066","volume":"491","author":"X Sun","year":"2024","unstructured":"Sun X, Huang W, Yin D, Zhao X, Cheng X, Zhang J, et al. Nicotinamide riboside activates SIRT3 to prevent paclitaxel-induced peripheral neuropathy. Toxicol Appl Pharmacol. 2024;491: 117066.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"30","key":"1687_CR111","doi-asserted-by":"publisher","first-page":"21082","DOI":"10.1074\/jbc.M114.569574","volume":"289","author":"K Janes","year":"2014","unstructured":"Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, et al. The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. J Biol Chem. 2014;289(30):21082\u201397.","journal-title":"J Biol Chem"},{"key":"1687_CR112","unstructured":"Anukriti Sharma KBJ, Alper Sen, Bihua Bie, Emily E. Rhoades, Courtney Hershberger, Mei Wei, N. Lynn Henry, Carla Bou Dargham, G. Thomas Budd, Joseph Foss, Daniel M. Rotroff Longitudinal multi-omics study reveals potential targets against chemotherapy induced peripheral neuropathy during taxane treatment SABCS abstract Number: P1\u201304\u201302. 2024.\u00a0https:\/\/sabcs.org\/Portals\/0\/Documents\/FINAL%20SABCS%2024%20%20Poster%20Session%201%20.pdf?ver=COtfEZSxfP5lWkHrNkFAqg%3D%3D."},{"key":"1687_CR113","doi-asserted-by":"crossref","unstructured":"Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, et al. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology\/NSABP B-30. JNCI: J Nat Cancer Inst. 2018;110(2):djx162.","DOI":"10.1093\/jnci\/djx162"},{"issue":"22","key":"1687_CR114","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","volume":"362","author":"SM Swain","year":"2010","unstructured":"Swain SM, Jeong J-H, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. N Engl J Med. 2010;362(22):2053\u201365.","journal-title":"N Engl J Med"},{"issue":"28","key":"1687_CR115","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325\u201348.","journal-title":"J Clin Oncol"},{"key":"1687_CR116","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.2147\/JPR.S488470","volume":"17","author":"Z Wan","year":"2024","unstructured":"Wan Z, Huang J, Wang X, Li P. Compression Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Pain Res. 2024;17:4509\u201319.","journal-title":"J Pain Res"},{"issue":"5","key":"1687_CR117","volume":"16","author":"M Okazaki","year":"2024","unstructured":"Okazaki M, Bando H, Terasaki A, Ueda A, Iguchi-Manaka A, Mathis BJ, et al. Safety and Efficacy of Compression Therapy to Prevent Chemotherapy-Induced Peripheral Neuropathy in Lower Extremities of Breast Cancer Patients: A Pilot Study. Cureus. 2024;16(5): e60998.","journal-title":"Cureus"},{"issue":"1","key":"1687_CR118","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-023-07172-y","volume":"204","author":"MK Accordino","year":"2024","unstructured":"Accordino MK, Lee S, Leu CS, Levin B, Trivedi MS, Crew KD, et al. Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer. Breast Cancer Res Treat. 2024;204(1):49\u201359.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1687_CR119","first-page":"260","volume":"32","author":"G Dongxue","year":"2024","unstructured":"Dongxue G, Ran L, Fangfei Z, Zirui Z, Lizhi Z. Therapeutic effects of compression therapy on taxane-induced peripheral neuropathy incidence, negative emotions, and sleep disorders in patients with breast cancer. Support Care Cancer. 2024;32(4):260.","journal-title":"Support Care Cancer"},{"issue":"8","key":"1687_CR120","first-page":"554","volume":"32","author":"K Johnson","year":"2024","unstructured":"Johnson K, Stoffel B, Schwitter M, Hayoz S, Rojas Mora A, Fischer Maranta A, et al. Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison. Support Care Cancer. 2024;32(8):554.","journal-title":"Support Care Cancer"},{"issue":"7","key":"1687_CR121","first-page":"482","volume":"32","author":"HY Tai","year":"2024","unstructured":"Tai HY, Lin LY, Huang TW, Gautama MSN. Efficacy of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Support Care Cancer. 2024;32(7):482.","journal-title":"Support Care Cancer"},{"key":"1687_CR122","unstructured":"Lendorf ME. Effects of cryotherapy on objective and subjective symptoms of taxane induced neuropathy in patients with early breast cancer: a national, multicenter, prospective, randomized, controlled trial. SABCS Abtract Number: 1-PS5\u201308. 2024.\u00a0https:\/\/sabcs.org\/Portals\/0\/Documents\/FINAL%20SABCS%2024%20%20Poster%20Session%201%20.pdf?ver=COtfEZSxfP5lWkHrNkFAqg%3D%3D."},{"key":"1687_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103763","volume":"76","author":"C Brunner","year":"2024","unstructured":"Brunner C, Emmelheinz M, Egle D, Ritter M, Leitner K, Wieser V, et al. Cropsi study: Efficacy and safety of cryotherapy and cryocompression in the prevention of chemotherapy-induced peripheral neuropathy in patients with breast and gynecological cancer-A prospective, randomized trial. Breast. 2024;76: 103763.","journal-title":"Breast"},{"issue":"12","key":"1687_CR124","first-page":"1388","volume":"44","author":"Y Yao","year":"2024","unstructured":"Yao Y, Zhang X, Ge R, Im HS, Yao C. Electroacupuncture for the prevention of chemotherapy-induced peripheral neuropathy: a randomized controlled trial. Zhongguo Zhen Jiu. 2024;44(12):1388\u201394.","journal-title":"Zhongguo Zhen Jiu"},{"issue":"6","key":"1687_CR125","first-page":"e436","volume":"28","author":"MC Huang","year":"2023","unstructured":"Huang MC, Chang SC, Liao WL, Ke TW, Lee AL, Wang HM, et al. Acupuncture May Help to Prevent Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Sham-Controlled. Single-Blind Study Oncologist. 2023;28(6):e436\u201347.","journal-title":"Single-Blind Study Oncologist"},{"issue":"8","key":"1687_CR126","first-page":"493","volume":"32","author":"M Aghili","year":"2024","unstructured":"Aghili M, Taherioun M, Jafari F, Azadvari M, Lashkari M, Kolahdouzan K, et al. Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial). Support Care Cancer. 2024;32(8):493.","journal-title":"Support Care Cancer"},{"issue":"6","key":"1687_CR127","first-page":"5509","volume":"30","author":"L Joy","year":"2022","unstructured":"Joy L, Jolien R, Marith\u00e9 C, Stijn E, Laura S, Hilde L, et al. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial). Support Care Cancer. 2022;30(6):5509\u201317.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1687_CR128","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1186\/s12885-023-11079-8","volume":"23","author":"YJ Kang","year":"2023","unstructured":"Kang YJ, Yoon CI, Yang YJ, Baek JM, Kim YS, Jeon YW, et al. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial). BMC Cancer. 2023;23(1):570.","journal-title":"BMC Cancer"},{"issue":"13","key":"1687_CR129","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359\u201367.","journal-title":"JAMA"},{"key":"1687_CR130","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3389\/fphar.2019.00365","volume":"10","author":"J Meng","year":"2019","unstructured":"Meng J, Zhang Q, Yang C, Xiao L, Xue Z, Zhu J. Duloxetine, a Balanced Serotonin-Norepinephrine Reuptake Inhibitor, Improves Painful Chemotherapy-Induced Peripheral Neuropathy by Inhibiting Activation of p38 MAPK and NF-\u03baB. Front Pharmacol. 2019;10:365.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1687_CR131","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/CAD.0000000000001005","volume":"32","author":"R Velasco","year":"2021","unstructured":"Velasco R, Besora S, Argyriou AA, Santos C, Sala R, Izquierdo C, et al. Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience. Anticancer Drugs. 2021;32(1):88\u201394.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"1687_CR132","first-page":"1019","volume":"26","author":"IR Kleckner","year":"2018","unstructured":"Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018;26(4):1019\u201328.","journal-title":"Support Care Cancer"},{"issue":"7","key":"1687_CR133","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/sms.14360","volume":"33","author":"S Nu\u00f1ez de Arenas-Arroyo","year":"2023","unstructured":"Nu\u00f1ez de Arenas-Arroyo S, Cavero-Redondo I, Torres-Costoso A, Reina-Guti\u00e9rrez S, Lorenzo-Garc\u00eda P, Mart\u00ednez-Vizca\u00edno V. Effects of exercise interventions to reduce chemotherapy-induced peripheral neuropathy severity: A meta-analysis. Scand J Med Sci Sports. 2023;33(7):1040\u201353.","journal-title":"Scand J Med Sci Sports"},{"key":"1687_CR134","doi-asserted-by":"publisher","unstructured":"Huang Y, Tan T, Liu L, Yan Z, Deng Y, Li G, Li M, Xiong J. Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. Front Neurol. 2024;14:1252259. https:\/\/doi.org\/10.3389\/fneur.2023.1252259. Erratum in: Front Neurol. 2024;15:1378461. https:\/\/doi.org\/10.3389\/fneur.2024.1378461. Erratum in: Front Neurol. 2024;15:1460992. https:\/\/doi.org\/10.3389\/fneur.2024.1460992.","DOI":"10.3389\/fneur.2023.1252259"},{"issue":"10","key":"1687_CR135","first-page":"677","volume":"32","author":"IR Kleckner","year":"2024","unstructured":"Kleckner IR, Manuweera T, Lin PJ, Chung KH, Kleckner AS, Gewandter JS, et al. Pilot trial testing the effects of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN) and the interoceptive brain system. Support Care Cancer. 2024;32(10):677.","journal-title":"Support Care Cancer"},{"issue":"12","key":"1687_CR136","first-page":"837","volume":"32","author":"RL Li","year":"2024","unstructured":"Li RL, Liu JE, Bai LX, Yang AL, Liu Y, Zhao FY, et al. Striding beyond numbness: a non-randomized controlled study of an exercise program for breast cancer patients with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2024;32(12):837.","journal-title":"Support Care Cancer"},{"issue":"10","key":"1687_CR137","first-page":"1139","volume":"44","author":"C Lu","year":"2024","unstructured":"Lu C, Feng X, Shen Q, Li G, Wu T, Li X, et al. Electroacupuncture with different frequencies for paclitaxel-induced peripheral neuropathy: a randomized controlled trial. Zhongguo Zhen Jiu. 2024;44(10):1139\u201345.","journal-title":"Zhongguo Zhen Jiu"},{"issue":"4","key":"1687_CR138","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1634\/theoncologist.2019-0489","volume":"25","author":"W Lu","year":"2020","unstructured":"Lu W, Giobbie-Hurder A, Freedman RA, Shin IH, Lin NU, Partridge AH, et al. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. Oncologist. 2020;25(4):310\u20138.","journal-title":"Oncologist"},{"issue":"4","key":"1687_CR139","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s11764-021-01081-z","volume":"16","author":"R Knoerl","year":"2022","unstructured":"Knoerl R, Giobbie-Hurder A, Berfield J, Berry D, Meyerhardt JA, Wright AA, et al. Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial. J Cancer Surviv. 2022;16(4):882\u201391.","journal-title":"J Cancer Surviv"},{"key":"1687_CR140","unstructured":"A Randomized Phase III Clinical Trial of Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) [Internet]. 2021. Available from: \nhttps:\/\/clinicaltrials.gov\/study\/NCT05121558. Accessed 22 Apr 2025."},{"key":"1687_CR141","unstructured":"A Randomized Phase III Clinical Trial of Acupuncture for Chemotherapy-induced Peripheral Neuropathy Treatment (ACT) [Internet]. 2021. Available from: \nhttps:\/\/clinicaltrials.gov\/study\/NCT04917796. Accessed 22 Apr 2025."},{"issue":"1","key":"1687_CR142","first-page":"43","volume":"33","author":"L Ran","year":"2024","unstructured":"Ran L, Dongxue G, Zirui Z, Jiwei H, Aijun D, Yuchen H, et al. Effects of intermittent hand-foot hypothermia therapy on chemotherapy-induced peripheral neurotoxicity. Support Care Cancer. 2024;33(1):43.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1687_CR143","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1186\/s12885-023-11560-4","volume":"23","author":"S Misawa","year":"2023","unstructured":"Misawa S, Denda T, Kodama S, Suzuki T, Naito Y, Kogawa T, et al. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study). BMC Cancer. 2023;23(1):1098.","journal-title":"BMC Cancer"},{"issue":"2","key":"1687_CR144","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/tbj.13196","volume":"25","author":"M Aghili","year":"2019","unstructured":"Aghili M, Zare M, Mousavi N, Ghalehtaki R, Sotoudeh S, Kalaghchi B, et al. Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial. Breast J. 2019;25(2):226\u201331.","journal-title":"Breast J"},{"issue":"9","key":"1687_CR145","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/cncr.23008","volume":"110","author":"RD Rao","year":"2007","unstructured":"Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110\u20138.","journal-title":"Cancer"},{"issue":"2","key":"1687_CR146","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/cncr.35027","volume":"130","author":"S Prinsloo","year":"2024","unstructured":"Prinsloo S, Kaptchuk TJ, De Ridder D, Lyle R, Bruera E, Novy D, et al. Brain-computer interface relieves chronic chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial. Cancer. 2024;130(2):300\u201311.","journal-title":"Cancer"},{"key":"1687_CR147","unstructured":"Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients [Internet]. 2021. Available from: \nhttps:\/\/clinicaltrials.gov\/study\/NCT05074290. Accessed 22 Apr 2025."},{"key":"1687_CR148","unstructured":"Sonia Servitja Maria Castro-Henriques I\u00c1-B, Miguel Servet, Carlota D\u00edez-Franco, Alba Medina-Castillo, Maria Asunci\u00f3n Algarra-Garc\u00eda, Marina Baixa, Villajoyosa, Alicante, Elena L\u00f3pez-Miranda, Ramon y Cajal, Margaret Lario-Mart\u00ednez, Ramon y Cajal, Maria Isabel Luengo-Alc\u00e1zar, Miguel Borreg\u00f3n, Ana Dav\u00f3, Elche, Alicante, Anna Gassull-Delgado, Sara Roque-Garc\u00eda, Ana Gonzaga-L\u00f3pez, Elda, Alicante, Jesus Manuel Poveda-Ferriols, Severine Pascal, Clotilde Ferr\u00e1ndiz-Huertas, Miguel Hern\u00e1ndez, Ana Mar\u00eda Mitroi-Marinescu, Marta Garc\u00eda-Escolano, Miguel Hern\u00e1ndez, Fern\u00e1ndez-Carvajal, Miguel Hern\u00e1ndez, Antonio Ferrer Montiel. Topical modulation of nociceptor epidermal terminals delays and ameliorates CIPN improving the quality of life of breast cancer patients. SABCS abstract Number: P1\u201302\u201307. 2024.\u00a0https:\/\/sabcs.org\/Portals\/0\/Documents\/FINAL%20SABCS%2024%20%20Poster%20Session%201%20.pdf?ver=COtfEZSxfP5lWkHrNkFAqg%3D%3D."},{"key":"1687_CR149","doi-asserted-by":"crossref","unstructured":"Li T, Timmins HC, Mahfouz FM, Trinh T, Mizrahi D, Horvath LG, et al. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy. JAMA Network Open. 2024;7(8):e2424139-e.","DOI":"10.1001\/jamanetworkopen.2024.24139"},{"key":"1687_CR150","doi-asserted-by":"crossref","unstructured":"Burton LB, Eskian M, Guidon AC, Reynolds KL. A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neuro-Oncology Advances. 2021;3(Supplement_5):v108-v20.","DOI":"10.1093\/noajnl\/vdab107"},{"issue":"4","key":"1687_CR151","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020;19(4):479\u201388.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"1687_CR152","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","volume":"21","author":"A DeMichele","year":"2015","unstructured":"DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, et al. CDK 4\/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment. Clin Cancer Res. 2015;21(5):995\u20131001.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1687_CR153","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/pmrj.13007","volume":"16","author":"SR Harris","year":"2024","unstructured":"Harris SR. Brachial plexopathy after breast cancer: A persistent late effect of radiotherapy. PM&R. 2024;16(1):85\u201391.","journal-title":"PM&R"},{"key":"1687_CR154","doi-asserted-by":"crossref","unstructured":"Pradat P-F, Delanian S. Chapter 43 - Late radiation injury to peripheral nerves. In: Said G, Krarup C, editors. Handbook of Clinical Neurology. 115: Elsevier; 2013. p. 743\u201358.","DOI":"10.1016\/B978-0-444-52902-2.00043-6"},{"key":"1687_CR155","first-page":"761","volume":"15","author":"F Avila","year":"2023","unstructured":"Avila F, Torres-Guzman R, Maita K, Garcia JP, De Sario GD, Borna S, et al. A Review on the Management of Peripheral Neuropathic Pain Following Breast Cancer. Breast Cancer (Dove Med Press). 2023;15:761\u201372.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"5","key":"1687_CR156","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1503\/cjs.000716","volume":"59","author":"D Waltho","year":"2016","unstructured":"Waltho D, Rockwell G. Post\u2013breast surgery pain syndrome: establishing a consensus for the definition of post-mastectomy pain syndrome to provide a standardized clinical and research approach \u2014 a review of the literature and discussion. Can J Surg. 2016;59(5):342\u201350.","journal-title":"Can J Surg"},{"issue":"3","key":"1687_CR157","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.apmr.2005.12.017","volume":"87","author":"MD Stubblefield","year":"2006","unstructured":"Stubblefield MD, Custodio CM. Upper-Extremity Pain Disorders in Breast Cancer. Arch Phys Med Rehabil. 2006;87(3):96\u20139.","journal-title":"Arch Phys Med Rehabil"},{"issue":"22","key":"1687_CR158","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-23-0757","volume":"29","author":"AJMB Medford","year":"2023","unstructured":"Medford AJMB, Spring LM, Hurvitz SA, Turner NC, Bardia A. Molecular residual disease in breast cancer: detection and therapeutic interception. Clin Cancer Res. 2023;29(22):4540\u20138.","journal-title":"Clin Cancer Res"},{"key":"1687_CR159","doi-asserted-by":"crossref","unstructured":"Garcia-Murillas I SG, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science translational medicine. 2015 7(302):302ra133-.","DOI":"10.1126\/scitranslmed.aab0021"},{"key":"1687_CR160","doi-asserted-by":"crossref","unstructured":"Gale D HK, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, Rundell V, Wulff J, Sharma G, Knock H, Castedo. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. J Annals of oncology. 2022;33(5):500\u201310.","DOI":"10.1016\/j.annonc.2022.02.007"},{"issue":"8","key":"1687_CR161","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"THT Reinert","year":"2019","unstructured":"Reinert THT, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Rasmussen MH. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124\u201331.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1687_CR162","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41523-023-00512-7","volume":"9","author":"SRKB Stecklein","year":"2023","unstructured":"Stecklein SRKB, Yoder R, Schwensen K, Staley JM, Khan QJ, O\u2019Dea AP, Nye LE, Elia M, Heldstab J, Home T. ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. NPJ Breast Cancer. 2023;9(1):10.","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"1687_CR163","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a003772","volume":"5","author":"TMBC Butler","year":"2019","unstructured":"Butler TMBC, Johnson-Camacho K, Tabatabaei S, Melendez D, Kelley T, Gray J, Corless CL, Spellman PT. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer. Molecular Case Studies. 2019;5(2): a003772.","journal-title":"Molecular Case Studies"},{"key":"1687_CR164","doi-asserted-by":"crossref","unstructured":"Garcia-Murillas I, et al. Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Ann Oncol. 36(6):673\u201381.","DOI":"10.1016\/j.annonc.2025.01.021"},{"key":"1687_CR165","unstructured":"Mergel F, Huesmann ST, Friedl TWP, Pfister K.\u00a0A multicenter, randomized, controlled phase 3 superiority trial, evaluating liquid biopsy-guided intensified follow-up surveillance in women with breast cancer. San Antonio Breast Cancer Symposium. 2023."},{"key":"1687_CR166","doi-asserted-by":"publisher","unstructured":"Welch HG, Dossett LA. Routine surveillance for cancer metastases - does it help or harm patients? N Engl J Med. 2025;392(17):1667\u201370. https:\/\/doi.org\/10.1056\/NEJMp2414159.","DOI":"10.1056\/NEJMp2414159"},{"key":"1687_CR167","doi-asserted-by":"publisher","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916\u201346. https:\/\/doi.org\/10.1200\/JCO.19.01696.","DOI":"10.1200\/JCO.19.01696"},{"issue":"3","key":"1687_CR168","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ctrv.2007.10.004","volume":"34","author":"RE Coleman","year":"2008","unstructured":"Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev. 2008;34(3):275\u201382.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"1687_CR169","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"ESB Amir","year":"2011","unstructured":"Amir ESB, Niraula S, Carlsson L, Oca\u00f1a A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299\u2013309.","journal-title":"J Natl Cancer Inst"},{"key":"1687_CR170","doi-asserted-by":"crossref","unstructured":"Goldvaser H BT, \u0160eruga B, Cescon DW, Oca\u00f1a A, Ribnikar D, Amir E. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. JNCI: J Nat Cancer Inst 2018;110 (1):31\u20139","DOI":"10.1093\/jnci\/djx141"},{"key":"1687_CR171","doi-asserted-by":"crossref","unstructured":"Yu Z, Sun D, Sun J. Social Support and Fear of Cancer Recurrence Among Chinese Breast Cancer Survivors: The Mediation Role of Illness Uncertainty. Front Psychol. 2022; 13 - 2022.","DOI":"10.3389\/fpsyg.2022.864129"},{"key":"1687_CR172","doi-asserted-by":"publisher","unstructured":"Luigjes-Huizer YL, van der Lee ML, Richel C, Masselink RA, de Wit NJ, Helsper CW. Patient-reported needs for coping with worry or fear about cancer recurrence and the extent to which they are being met: a survey study. J Cancer Surviv. 2024;18(3):791\u20139. https:\/\/doi.org\/10.1007\/s11764-022-01326-5.","DOI":"10.1007\/s11764-022-01326-5"},{"issue":"1","key":"1687_CR173","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12885-023-11087-8","volume":"23","author":"R Fan","year":"2023","unstructured":"Fan R, Wang L, Bu X, Wang W, Zhu J. Unmet supportive care needs of breast cancer survivors: a systematic scoping review. BMC Cancer. 2023;23(1):587.","journal-title":"BMC Cancer"},{"issue":"3","key":"1687_CR174","first-page":"1049","volume":"27","author":"O Mart\u00ednez Arroyo","year":"2019","unstructured":"Mart\u00ednez Arroyo O, Andreu Va\u00edllo Y, Mart\u00ednez L\u00f3pez P, Gald\u00f3n Garrido MJ. Emotional distress and unmet supportive care needs in survivors of breast cancer beyond the end of primary treatment. Support Care Cancer. 2019;27(3):1049\u201357.","journal-title":"Support Care Cancer"},{"issue":"6","key":"1687_CR175","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","volume":"34","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34(6):611\u201335.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1687_CR176","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.31557\/APJCP.2024.25.5.1787","volume":"25","author":"M Zarei","year":"2024","unstructured":"Zarei M, Sharif-Nia H, Lehto RH, Goudarzian AH, Ashghali-Farahani M. Relationship Between Fear of Cancer Recurrence and Quality of Life in Patients Undergoing Active Cancer Treatment: The Mediating Role of Social Support. Asian Pac J Cancer Prev. 2024;25(5):1787\u201393.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"12","key":"1687_CR177","first-page":"656","volume":"31","author":"BA Jansen","year":"2023","unstructured":"Jansen BA, Bargon CA, Dinger TL, van den Goor M, Postma EL, Young-Afat DA, et al. Breast cancer patients\u2019 needs and perspectives on a one-on-one peer support program: quantitative and qualitative analyses. Support Care Cancer. 2023;31(12):656.","journal-title":"Support Care Cancer"},{"issue":"2","key":"1687_CR178","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/0284186X.2023.2180326","volume":"62","author":"A Elsous","year":"2023","unstructured":"Elsous A, Radwan M, Najjar S, Masad A, Abu RM. Unmet needs and health-related quality of life of breast cancer survivors: survey from Gaza Strip. Palestine Acta Oncol. 2023;62(2):194\u2013209.","journal-title":"Palestine Acta Oncol"},{"issue":"4","key":"1687_CR179","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/jocn.16963","volume":"33","author":"Q Dai","year":"2024","unstructured":"Dai Q, Liu X, Xu X, Fu Y, She Z, Huang Y, et al. Development of a supportive care framework for breast cancer survivor\u2019s unmet needs: A modified Delphi study. J Clin Nurs. 2024;33(4):1376\u201386.","journal-title":"J Clin Nurs"},{"issue":"8","key":"1687_CR180","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/bjc.2017.283","volume":"117","author":"M Capelan","year":"2017","unstructured":"Capelan M, Battisti NML, McLoughlin A, Maidens V, Snuggs N, Slyk P, et al. The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer. Br J Cancer. 2017;117(8):1113\u201320.","journal-title":"Br J Cancer"},{"issue":"22","key":"1687_CR181","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1200\/JCO.22.00687","volume":"40","author":"JA Ligibel","year":"2022","unstructured":"Ligibel JA, Bohlke K, May AM, Clinton SK, Demark-Wahnefried W, Gilchrist SC, et al. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol. 2022;40(22):2491\u2013507.","journal-title":"J Clin Oncol"},{"key":"1687_CR182","doi-asserted-by":"crossref","unstructured":"Shen S, Liu B, Fanti C, Bromberg M, Chen Y, Chang C, et al. Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer. J Clin Oncol. 2024;42(16_suppl):10607-.","DOI":"10.1200\/JCO.2024.42.16_suppl.10607"},{"key":"1687_CR183","doi-asserted-by":"crossref","unstructured":"Fischbach NA, Zhou B, Deng Y, Parsons K, Shelton A, Lustberg MB. Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer. J Clin Oncol. 2024;42(16_suppl):e24140-e.","DOI":"10.1200\/JCO.2024.42.16_suppl.e24140"},{"issue":"5","key":"1687_CR184","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","volume":"163","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022;163(5):1198\u2013225.","journal-title":"Gastroenterology"},{"issue":"6","key":"1687_CR185","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12032-024-02390-w","volume":"41","author":"H Ligumsky","year":"2024","unstructured":"Ligumsky H, Amir S, Arbel Rubinstein T, Guion K, Scherf T, Karasik A, et al. Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells. Med Oncol. 2024;41(6):138.","journal-title":"Med Oncol"},{"issue":"12","key":"1687_CR186","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/en.2017-00461","volume":"158","author":"C Iwaya","year":"2017","unstructured":"Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, Hamaguchi Y, et al. Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-\u03baB Activation. Endocrinology. 2017;158(12):4218\u201332.","journal-title":"Endocrinology"},{"key":"1687_CR187","doi-asserted-by":"crossref","unstructured":"Levy S, Attia A, Elshazli RM, Abdelmaksoud A, Tatum D, Aiash H, et al. Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients. Cancers (Basel). 2024;17(1).","DOI":"10.3390\/cancers17010078"},{"key":"1687_CR188","doi-asserted-by":"publisher","unstructured":"Sarfraz H, Bari S, Eysha M, Patel K, Dutta T, Gardell S, et al. Safety and efficacy of time restricted eating (Tre) in improving response to immunotherapy in patients with head and neck cancer (Hnscc). Am Soc Clin Oncol. 2023;31:6051. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.605.","DOI":"10.1200\/JCO.2023.41.16_suppl.605"},{"issue":"1","key":"1687_CR189","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s13063-023-07672-8","volume":"24","author":"J Ivory","year":"2023","unstructured":"Ivory J, Wheeler SB, Drier S, Gunn H, Zahrieh D, Paskett E, et al. Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol. Trials. 2023;24(1):664.","journal-title":"Trials"},{"issue":"34","key":"1687_CR190","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1200\/JCO.23.00871","volume":"41","author":"T Sanft","year":"2023","unstructured":"Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li FY, et al. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. J Clin Oncol. 2023;41(34):5285\u201395.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1687_CR191","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1200\/JCO.23.01428","volume":"42","author":"CE Geyer","year":"2024","unstructured":"Geyer CE, Blum JL, Yothers G, Asmar L, Flynn PJ, Robert NJ, et al. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06\u2013090, NSABP B-46-I\/USOR 07132, and NSABP B-49 [NRG Oncology]). J Clin Oncol. 2024;42(12):1344\u20139.","journal-title":"J Clin Oncol"},{"key":"1687_CR192","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","volume":"185","author":"WCM Dempke","year":"2023","unstructured":"Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W. Anthracycline-induced cardiotoxicity & #x2014; are we about to clear this hurdle? Eur J Cancer. 2023;185:94\u2013104.","journal-title":"Eur J Cancer"},{"key":"1687_CR193","doi-asserted-by":"crossref","unstructured":"Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985\u20132010. JAMA Network Open. 2023;6(2):e2254669-e.","DOI":"10.1001\/jamanetworkopen.2022.54669"},{"key":"1687_CR194","first-page":"26","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines Front Cardiovasc Med. 2020;7:26.","journal-title":"Cardiotoxicity of Anthracyclines Front Cardiovasc Med"},{"issue":"41","key":"1687_CR195","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"10","key":"1687_CR196","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2011.37.0189","volume":"30","author":"V Koppelmans","year":"2012","unstructured":"Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1687_CR197","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/S1470-2045(18)30938-0","volume":"20","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Parsons MW, Dietrich J. Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol. 2019;20(2):e92\u2013102.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1687_CR198","first-page":"1185","volume":"21","author":"DL Barton","year":"2013","unstructured":"Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, et al. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer. 2013;21(4):1185\u201392.","journal-title":"Support Care Cancer"},{"key":"1687_CR199","doi-asserted-by":"crossref","unstructured":"Treanor CJ, McMenamin UC, O'Neill RF, Cardwell CR, Clarke MJ, Cantwell M, et al. Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment. Cochrane Database Syst Rev. 2016;2016(8):Cd011325.","DOI":"10.1002\/14651858.CD011325.pub2"},{"issue":"5","key":"1687_CR200","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/sj.bjc.6604241","volume":"98","author":"YM Kirova","year":"2008","unstructured":"Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 2008;98(5):870\u20134.","journal-title":"Br J Cancer"},{"issue":"3","key":"1687_CR201","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3892\/mco.2014.250","volume":"2","author":"C Dong","year":"2014","unstructured":"Dong C, Chen L. Second malignancies after breast cancer: The impact of adjuvant therapy. Mol Clin Oncol. 2014;2(3):331\u20136.","journal-title":"Mol Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01687-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T02:03:55Z","timestamp":1757556235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01687-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":201,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1687"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01687-x","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"7 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}